Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
ATHLONE, Ireland, Nov. 23, 2016 -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need, today announced that Anthony Zook, Chief Executive Officer of Innocoll Holdings plc, will participate in a fireside chat at the Piper Jaffray Annual Healthcare Conference on Wednesday, November 30, 2016, at 1:30 p.m. ET at the Lotte New York Palace Hotel in New York, NY.
About Innocoll Holdings plc
Innocoll is a global, specialty pharmaceutical company with late stage development programs that is dedicated to engineering better medicines to help patients get better. Our proprietary, biocompatible, and biodegradable collagen products are precision-engineered for targeted use. Applied locally to surgery sites, they are designed to provide a range of benefits. The company's late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XARACOLL for the treatment of postoperative pain and COLLAGUARD (INL-003), a barrier for the prevention of post-surgical adhesions.
Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®.
Corporate: Pepe Carmona Chief Financial Officer (215) 983-3362 [email protected] Jeannie Sorenson, M.D. Vice President, Investor Relations (314) 458-7355 [email protected]
